Want to see NIKI full AI Analyst Report?
NIKI Stock Chart & Stats
$7.90
-$0.20(-2.33%)
At close: 4:00 PM EDT
$7.90
-$0.20(-2.33%)
Day’s Range― - ―
52-Week Range$5.68 - $25.89
Previous CloseN/A
Volume50.61K
Average Volume (3M)176.90K
Market Cap
$16.57M
Enterprise Value-$2.15
Total Cash (Recent Filing)$3.45M
Total Debt (Recent Filing)$3.44M
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Sep 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.20
Shares Outstanding2,723,024
10 Day Avg. Volume461,251
30 Day Avg. Volume176,896
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)0.34
Price to Sales (P/S)0.00
P/FCF Ratio-4.24
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)31
Revenue Forecast (FY)$106.80M
Bulls Say, Bears Say
Bulls Say
Supportive Balance SheetA relatively resilient balance sheet gives this development-stage biotech a buffer while it advances candidates and funds operations. Improved leverage and sizable equity may preserve financial flexibility, although that support depends on containing continued losses.
Losses And Cash Burn Have Recently NarrowedRecent improvement in losses and cash usage suggests some progress in operating discipline, even though the company remains unprofitable and cash-flow negative. If sustained, lower burn could extend funding runway and support continued development of its therapeutic pipeline.
Leadership Aligned With Fundraising And Merger ExecutionInstalling senior leadership during a merger and linking part of compensation to fundraising creates clearer accountability for execution and capital access. This alignment could help the company advance its pipeline and pursue partnerships, provided management delivers the targeted financing.
Bears Say
Commercial Revenue Has Collapsed To Near ZeroThe absence of meaningful recent revenue shows that the company has not yet established commercial scale or a recurring operating revenue base. This leaves value dependent on successful clinical development, partnering, or future commercialization rather than current product demand.
Persistent Operating And Net LossesSustained operating and net losses indicate that the business is consuming resources without demonstrating an established path to profitability. Continued losses can erode equity over time and increase the importance of successful pipeline milestones or external financing.
Ongoing Negative Cash GenerationPersistent negative operating and free cash flow means internal operations do not currently fund research and corporate needs. Reliance on external capital can constrain strategic flexibility and expose the company to funding pressure if development spending continues before products generate revenue.
Niki BioSolutions Inc News
NIKI FAQ
What was Niki BioSolutions Inc’s price range in the past 12 months?
Niki BioSolutions Inc lowest stock price was $5.68 and its highest was $25.89 in the past 12 months.
What is Niki BioSolutions Inc’s market cap?
Niki BioSolutions Inc’s market cap is $16.57M.
When is Niki BioSolutions Inc’s upcoming earnings report date?
Niki BioSolutions Inc’s upcoming earnings report date is Sep 15, 2026 which is tomorrow.
How were Niki BioSolutions Inc’s earnings last quarter?
Niki BioSolutions Inc released its earnings results on Sep 16, 2025. The company reported -$0.062 earnings per share for the quarter.
Is Niki BioSolutions Inc overvalued?
According to Wall Street analysts Niki BioSolutions Inc’s price is currently Overvalued.
Does Niki BioSolutions Inc pay dividends?
Niki BioSolutions Inc does not currently pay dividends.
What is Niki BioSolutions Inc’s EPS estimate?
Niki BioSolutions Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Niki BioSolutions Inc have?
Niki BioSolutions Inc has 2,723,024 shares outstanding.
What happened to Niki BioSolutions Inc’s price movement after its last earnings report?
Niki BioSolutions Inc reported an EPS of -$0.062 in its last earnings report. Following the earnings report the stock price went down -2.33%.
Which hedge fund is a major shareholder of Niki BioSolutions Inc?
Currently, no hedge funds are holding shares in NIKI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Niki BioSolutions Inc
Niki BioSolutions is a biopharmaceutical company that resulted from the merger of Aptorum Group and DiamiR Biosciences. The company focuses on developing and commercializing a diverse portfolio of therapeutic and diagnostic assets. Its work spans from treatments for diseases with unmet medical needs, particularly in oncology and infectious diseases, to the development of innovative, blood-based diagnostic tests for brain health and other conditions.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.22% Other Institutional Investors
99.78% Public Companies and
Individual Investors